Besponsa (inotuzumab ozogamicin) / Pfizer - LARVOL DELTA

Efficacy and Safety of the Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation. (PubMed, Am J Hematol) - No abstract available

Journal • Minimal residual disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation

EFFICACY AND SAFETY OF THE THIRD-GENERATION TYROSINE KINASE INHIBITOR OLVEREMBATINIB IN COMBINATION WITH INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULT PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH RELAPSED DISEASE OR PERSISTENT MINIMAL RESIDUAL DISEASE BRIDGING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PHASE II STUDY (EHA 2025) - P=N/A | "The findings of this study suggest that in Ph+ ALL patients with disease recurrence and persistent MRD positivity, the combination of olverembatinib and INO has a profound molecular response rate and is well tolerated in patients with MRD clearance prior to allo-HSCT."

Clinical • Combination therapy • Minimal residual disease • P2 data • Residual disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Lymphoma • Oncology • Transplantation • ABL1 • BCR • CD22

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (ASH 2025) - "Tyrosine kinase inhibitor (TKI) + blinatumomab regimenshave demonstrated high MR4 rates and favorable overall survival (OS); however, these regimens includeup to 5 courses of blinatumomab which is a continuous 28-day infusion (Kantarjian et al, JCO 2024; Foa etal, JCO 2024)...Eligibilitycriteria includes newly diagnosed Ph+ ALL, age ≥ 18, ECOG ≤2, CD22+ on ≥20% blasts, and no centralnervous system (CNS) disease.Schema 1 was as follows; Course (C) 1 was (28 days) dasatinib (DAS) 140mg daily, dexamethasone (dex)10mg/m2 D1-7 & D15-21, and InO 0.8mg/m2 D8, 0.5mg/m2 D15 and D22...If MR4 was not achieved by end of C2 (EOC2), DAS was switched to ponatinib(PON)...TKI + InO-based therapy for newly diagnosed pts with Ph+ ALL has an MR3+ rate of 81% within 2 coursesand 100% of pts achieved MR4 and/or NGS MRD- disease by EOC3. No cases of VOD were seen withSchema 2. Given the excellent rates of MR3+ with limited cycles of InO, further development of thisinduction approach is..."

Clinical • P2 data • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Pulmonary Disease • Respiratory Diseases • Septic Shock • IKZF1

Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study. (ASCO 2023) - P1/2 | " Pts ≥18 years with R/R Ph-negative B- or T-cell ALL received mini-HCVD alternating with methotrexate and cytarabine for up to 8 cycles...Rituximab (if CD20+ B-ALL) and prophylactic IT chemotherapy x8 doses were given for the first 4 cycles. Pts with T-ALL received additional 2 cycles of nelarabine and peg-asparaginase during consolidation without Ven, and 2 cycles during maintenance. Maintenance with vincristine, prednisone and Ven was given for up to 2 years...Among the 18 B-ALL pts, 16 (89%) had received prior blinatumomab and 7 (39%) prior inotuzumab... The combination of low-intensity chemotherapy mini-HCVD with Ven in pts with R/R Ph-negative ALL was well-tolerated and resulted in a response rate of 67%. Further studies examining the role of Ven-based therapies in ALL are needed for newly diagnosed and R/R pts. Clinical trial information: NCT03808610."

Clinical • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • CD20

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial (ASH 2025) - P1 | "Due to distinct mechanisms of action and non-overlapping toxicities, we hypothesized that adding VEN to INO would be safe and effective. This investigator-sponsored phase I study (NCT05016947) enrolled pts ≥18 years with CD22+ (≥20% ofblasts) R/R ALL (≥5% bone marrow [BM] blasts) or lymphoblastic lymphoma (LBL, BM <5% blasts).Philadelphia chromosome-negative (Ph-) pts had received ≥1 line of therapy; Ph+ pts were ponatinib(PON)-refractory or ineligible...Dexamethasone (10 mg/m2) was given during Lead-In and D1-4 of C1 Induction...BH3 profiling showed that ptsMRD- by C2 had lower pre-treatment mitochondrial apoptotic priming.Of the 21 CR patients, 1 pt (KMT2Ar) progressed during C2, and the remaining 20 pts (95.2%) wereconsolidated with blinatumomab (n=9, 42.9%), SCT (n=14, 66.7%, 6 after blinatumomab), DLI (n=1), XRT(n=1), or POMP (n=1)... VEN can be safely added to INO in pts with R/R CD22+ ALL/LBL including Ph+ ALL, with a very high anddurable rate of MRD- CR...."

P1 data • CNS Disorders • Febrile Neutropenia • Gastrointestinal Disorder • Hepatology • Lymphoblastic Lymphoma • Lymphoma • Neutropenia • Thrombocytopenia • KMT2A

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy. (PubMed, Haematologica) - "Not available."

Journal

High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701) (ASH 2025) - P2 | "Based upon retrospectivedata showing low rates of relapse, we hypothesized that patients with negative pre-HCT MRD by next-generation-sequencing of IgH B-cell receptor rearrangements (NGS-MRD) could achieve 2-year EFSexceeding 75% with a non-TBI regimen, an outcome comparable to those receiving TBI-based regimens. The Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) conducted a phase IIprospective trial at 45 Centers in North America (ONC1701 EndRAD: NCT03509961) between 2018 and2025 to evaluate outcomes of myeloablative non-TBI conditioning regimens for allogeneic HCT in B-ALLpatients at lower risk for relapse defined by absence of NGS-MRD (Clonoseq) of B-cell receptorrearrangements (BCR) just prior to HCT...Mismatched related/haploidentical grafts received post-transplant cyclophosphamide orTCRαβ/CD19 depletion according to institutional preference...Of patientsenrolled, 33% were White/Non-Hispanic, 37% Hispanic, 12% Black or African American, and..."

Biomarker • Clinical • IO biomarker • Minimal residual disease • Next-generation sequencing • Residual disease • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial (ASH 2022) - P1/2 | "The median age was 39 years (range, 21-82) and pts had received a median of 5 (range, 2-9) prior therapies [inotuzumab ozogamicin 12/21 (57%); blinatumomab 18/21 (86%); venetoclax 12/21 (57%)]. In this phase 1 study in pts with very heavily pretreated R/R B-ALL with a median of 5 prior lines of therapy and high baseline bone marrow tumor burden, single-agent ADCT-602 was well tolerated with one pt with DLT noted at the 50µg/kg weekly dose level. Notably, all 3 pts treated at this dose level had evidence of clinical activity with 2/3 pts achieving MRD negative CR. Due to 1 pt with DLT at this dose level, this cohort is being expanded to treat 3 additional pts."

Clinical • IO biomarker • P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Oncology • Thrombocytopenia • CD19 • CD22 • JAK2 • KRAS • PAX5 • TP53

Healthcare Resource Use and Economic Burden of B-Cell Acute Lymphoblastic Leukemia for Patients in the United States (SOHO 2026) - "Exclusions were pre-index B-ALL therapy, clinical trial participation, hospice, refractory or relapsed B-ALL, other B-cell malignancies or acute myeloid leukaemia, and daratumumab or nelarabine at baseline...Therapy included chemotherapy/rituximab (88.1%), TKIs (35.2%), blinatumomab (18.0%), inotuzumab (4.6%), and CAR-T (0.23%)... Adult US-based patients with B-ALL experience substantial and sustained economic burden following treatment initiation, with higher HCRU and costs driven primarily by medication, particularly advanced targeted therapies. Quantified, medication-driven costs following initiation give payers and providers actionable inputs for budget forecasting, and establish benchmarks to support value assessments for advanced therapies. Future research should stratify by treatment line and clinical risk, incorporate episode-based cost attribution, and include outcomes-adjusted evaluations to inform value."

Clinical • HEOR • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

Incorporating Immunotherapy into Upfront ALL Therapy (SOHO 2024) - "Treatment of B-lineage acute lymphoblastic leukemia (B-ALL) has seen notable improvement in outcomes in the past few years with the advent of the use of pediatric-intensive regimens for adolescents and young adults, the use of measurable residual disease (MRD) for risk assessment, and the introduction of potent immunotherapeutic agents, including blinatumomab (Blin), inotuzumab ozogamicin (InO), and chimeric-antigen receptor T-cell (CAR-T) therapy...8 The United States intergroup E1910 trial treated Ph-neg B-ALL adults (age range of 30–70 years) with 2 months of induction chemotherapy followed by an intensification cycle of high-dose methotrexate and pegaspargase for central nervous system (CNS) prophylaxis...The estimated EFS and OS rates were 95% and 95%, respectively.13 The U.S. intergroup is currently conducting a phase III randomized trial of dasatinib or ponatinib (investigator’s choice) with HyperCVAD or blinatumomab in patients aged 18–70 years with newly..."

IO biomarker • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22 • IKZF1

A REAL-WORLD STUDY OF INOTUZUMAB OZOGAMICIN COMBINED WITH VENETOCLAX AS FRONTLINE THERAPY FOR NEWLY-DIAGNOSED PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH SEVERE COMORBIDITY (EHA 2026) - P | "1 cycle of induction cycle consists of INO 1mg at day1, day8, day15; VEN 100mg at day1, 200mg at day2, 400mg from day3 to day21 orally; Methylprednisolone 1mg/kg for 2 weeks followed by a 2-weeks taper. Table 1. Baseline characteristics and responses of all patients"

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hepatology • Neutropenia • Thrombocytopenia • CD22

A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. (PubMed, Blood Adv) - "Thirteen patients (59%) had undergone prior allogeneic stem cell transplant (alloSCT), and 7 of 18 patients (39%) with B-cell ALL had previously received both inotuzumab ozogamicin and blinatumomab. Overall, the combination of mini-hyper-CVD plus venetoclax was active in heavily pretreated relapsed/refractory ALL. Further development of venetoclax-based combinations in ALL is warranted."

Journal • P1/2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Neutropenia • Transplantation

Utilization of BCMA-Directed Therapies in Plasmablastic Lymphoma: A Systematic Review (SOHO 2026) - "Patients had received two to five prior lines of therapy, including anthracycline-based induction (DAEPOCH ± bortezomib, CHOP), salvage chemotherapy, daratumumab, novel agents (ibrutinib, venetoclax, brentuximab vedotin, inotuzumab ozogamicin), humanized CD19 CAR-T, atezolizumab, and stem cell transplantation. BCMA-directed treatments were administered as third- to fifth-line therapy: 4 received teclistamab and 2 received BCMA-directed CAR-T therapy (1 cilta-cel, 1 autologous construct)... BCMA-targeted therapies, including teclistamab and BCMA-directed CAR-T approaches, achieve high rates of CR with manageable toxicity in heavily pretreated R/R PBL, offering promise for a disease with limited treatment options.Questions remain regarding durability of response, optimal sequencing with stem cell transplantation, and efficacy in HIV-positive vs HIV-negative populations. Further prospective studies are needed to clarify the role of BCMA-directed therapy in this rare..."

Review • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Intestinal Carcinoma

Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial. (PubMed, JAMA Oncol) - P1 | "Inotuzumab ozogamicin (InO) has been combined with low-intensity chemotherapy, with modest improvements over historical controls, and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) treatment is safe and active for newly diagnosed ALL. Further investigation of this combination is warranted. ClinicalTrials.gov Identifier: NCT03991884."

Journal • P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Transplantation • CD22

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) (ASH 2025) - P1/2 | "Sixteen pts (46%) were previously treated with blinatumomaband 13 pts (37%) with inotuzumab...CRS management includedtocilizumab (70%), siltuximab (10%), corticosteroids (40%), tocilizumab plus corticosteroids (37%), andanakinra (7%)...Seven pts received supportive measures for ICANS,including dexamethasone (5 pts, 71%) and anakinra (3 pts, 43%)... Phase 1 results with long follow-up suggest rapcabtagene autoleucel is active with highcellular expansion, durable efficacy for DL2–DL4, and a manageable safety profile in adult pts with r/r B-ALL. DL3—at which 92% of pts achieved BOR of CR/CRi by 3 mo, with median DOR not reached after 22mo median follow-up—exhibited an acceptable balance of safety, efficacy, and cellular expansion."

Clinical • P1 data • Acute Lymphocytic Leukemia • Aplastic Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukemia • Neutropenia • Rare Diseases

Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial. (ASH 2025) - P1/2 | "Leukapheresis could be followed by further chemo-immunotherapy and then standard lymphodepletion (LD) with fludarabine-cyclophosphamide beforebrexucel infusion...Adverse events included cytokine release syndrome (CRS) in 8 (57%) pts (all grade 1); 3 pts neededsingle dose tocilizumab... From Dec 2024-July 31 2025, 28 pts have had leukapheresis,18 pts were infused and 14 pts with afollow-up (FU) >1 month post brexucel infusion were included in this report. The median age of theinfused pts was 35 years (range 19-77), and 5 pts (36%) were ³60 years of age. Ten pts (71%) receivedbrexcuel as FL consolidation therapy for adverse genomics, 3 FL pts (21%) had persistent (n=2)/recurrent(n=1) MRD, and 1 (7%) pt had R/R ALL."

Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Inflammation • Leukemia • KMT2A • TP53

Efficacy of Inotuzumab Ozogamicin When Used as Salvage/Bridging Therapy Prior to CD19-Directed CAR-T Therapy in Relapsed/Refractory B-ALL: A Single-Center Experience (SOHO 2026) - "We evaluated the safety and efficacy of InO prior to talicabtagene autoleucel (Tali-cel)...Following fludarabine-cyclophosphamide conditioning, patients received either a single Tali-cel infusion of 5 × 106 or more CAR T cells/kg...Specifically, 15% received single-agent InO, while the remainder received combination therapy, most commonly mini-hyper-CVD (54.3%); ponatinib was the most common TKI used... InO achieved durable responses as salvage/bridging therapy in patients with R/R B-ALL, enabling 96% of patients to proceed to CAR-T therapy with acceptable toxicity profile. CAR-T: chimeric antigen receptor T-cell, CD: cluster of differentiation, CRS: cytokine release syndrome; CVD: cyclophosphamide, vincristine, dexamethasone; IEC-HS: immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome; InO: inotuzumab ozogamicin; MRD: measurable residual disease; OS: overall survival; PFS:..."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

A Literature Review of Immunotherapeutics in the Management of Adult B-Cell Acute Lymphoblastic Leukemia. (PubMed, Blood Lymphat Cancer) - "Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy have substantially improved patient outcomes in the R/R disease settings while reducing reliance on intensive cytotoxic chemotherapy, and their use has increasingly expanded into the frontline setting as well. We also provide our perspective on how these agents can be incorporated into clinical practice and highlight emerging therapeutic agents and strategies. In conclusion, continued advancement and earlier integration of immunotherapeutic approaches could improve long-term outcomes in patients with B-ALL."

Journal • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities. (PubMed, Clin Lymphoma Myeloma Leuk) - "A major focus was immunotherapy integration into frontline therapy, particularly blinatumomab as an emerging standard of care and inotuzumab ozogamicin as an investigational agent, and their potential to enable chemotherapy de-escalation. The integration of immunotherapy into frontline ALL therapy represents a paradigm shift with potential to improve outcomes while reducing treatment burden. However, careful attention to CNS disease control, emerging toxicities, and preservation of the remarkable achievements in childhood ALL therapy remains essential as the field advances."

Journal • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Oncology

Frontline therapies for adult patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a systematic literature review. (PubMed, Hematology) - "Frontline inotuzumab (±blinatumomab) plus chemotherapy showed promise in older populations, while the efficacy benefit of rituximab was inconclusive. No new safety signals were identified in the frontline setting for targeted therapies."

Journal • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin. (PubMed, Target Oncol) - "Efficacy/safety outcomes with InO were consistent across BMI subgroups. Dose-capping does not appear to be required."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Obesity • Oncology • Transplantation

INOTUZUMAB OZOGAMICIN IN PEDIATRIC CD22-POSITIVE VERY HIGH RISK FIRST RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF THE ITCC-059 STUDY (EHA 2025) - "Two cases of SOS gr3 were reported, both occurred in transplanted pts and resolved after treatment with defibrotide. InO showed high efficacy as reinduction treatment in pediatric VHR 1st rel BCP-ALL. New combination strategies to further improve outcomes are needed in pts with HR genetics (in particular TP53 mut/del), which may include bcl2 or menin inhibitors."

Clinical • Acute Lymphocytic Leukemia • Pediatrics • BCL2 • CD22 • KMT2A • PBX1 • TP53

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes (ASH 2024) - P2 | "In phase IA, phase II and stratum III, patients received single agent InO; while in phase IB InO was combined with vincristine and dexamethasone...Overall, 14 (13%) patients developed SOS, 2 during treatment, 10 after HSCT, and 2 after subsequent chemotherapy including high-dose methotrexate and cyclophosphamide...All SOS cases received treatment with defibrotide, except one patient in which SOS resolved with supportive management...The time between last InO and HSCT seems a significant risk factor for developing SOS, as in previous studies in adults treated with gemtuzumab ozogamicin. Taking into account also the longer median half-life of InO in pediatrics (T1/2 423 h,17.6 days; Trial NCT02981628), a minimum interval of 35 days after last InO dose and HSCT could be considered based on these data."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Hepatology • Leukemia • Oncology • Pediatrics • Septic Shock • CD22

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial. (PubMed, Lancet Haematol) - P1/2 | "Inotuzumab ozogamicin showed high activity as reinduction treatment in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse and a favourable toxicity profile with no treatment-related deaths."

Journal • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Neutropenia • Oncology • Pediatrics • Respiratory Diseases • Thrombocytopenia • Transplantation • AFF1 • CD22 • PBX1 • TCF3

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (clinicaltrials.gov) - P1/2 | N=44 | Recruiting | Sponsor: Leland Metheny | Trial primary completion date: Nov 2025 ➔ Nov 2026

Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD22